incapacitating asthma. It is quite improbable that a substantial portion ofthe observed increase in disabling asthma could be artefactual. 
rheumatoid arthritis were randomly allocated to receive pulses of either methylprednisolone or saline every four weeks for six months. At the start of the pulse treatment all patients were started on penicillamine or azathioprine.
Setting-Four rheumatology departments in
Denmark.
Patients-97 Patients (71 women, 26 men) aged 23-84 (mean 60) who had active rheumatoid arthritis of at least four weeks' duration despite treatment with non-steroidal anti-inflammatory drugs.
Main outcome measures-Monthly clinical recording of morning stiffness, number of tender and swollen joints, blinded observers' evaluation of therapeutic effect, and patients' self assessed condition. Concomitant laboratory measurements of erythrocyte sedimentation rate and concentrations of C reactive protein and haemoglobin. Radiography to determine the number of erosions at the start of treatment and after 12 months.
Results-57 Patients completed the trial, taking the same disease modifying drug throughout. Evaluation four weeks after each pulse treatment and at 12 month follow up showed no significant differences between the methylprednisolone and placebo groups in any of the clinical or laboratory variables. Radiography showed the same degree of progression of erosions in both groups. Evaluation of the total data on 97 patients and on the 57 who completed the trial showed the same lack of significance between the treatment groups.
Conclusions-Intravenous pulse treatment with steroids can be recommended only for rapid tempor 
Results
Of the 97 patients included in the trial, 57 completed it, taking the same disease modifying antirheumatic drug throughout (azathioprine plus methylprednisolone, 11 patients; azathioprine plus placebo, eight patients; penicillamine plus methylprednisolone, 20 patients; penicillamine plus placebo, 18 patients). Eleven patients changed treatment from penicillamine to azathioprine during the study, and 29 were withdrawn from the study owing to adverse reactions or lack of effect during treatment with azathioprine.
The characteristics of the patients and the activity of the disease before treatment were similar in the methylprednisolone and placebo groups (table I). In the methylprednisolone group 29 patients were started on penicillamine and 21 on azathioprine compared with 33 and 14 respectively in the placebo group.
Evaluation four weeks after each of the six pulse infusions and after 12 months showed no significant differences among the four treatment groups. Similarly, no differences were found in the number of tender and swollen joints, the patient's and the blinded observer's assessment of activity of disease, duration of morning stiffness, erythrocyte sedimentation rate, and concentrations of C reactive protein and haemoglobin. An identical progression of erosions was observed after one year among the four groups.
A comparison of clinical, biochemical, and radiographic findings in the patients given methylprednisolone and those given placebo showed no significant improvement among those receiving methylprednisolone (table II) . Evaluation of the data on all 97 patients as well as those on the 57 who completed the trial without changing their disease modifying antirheumatic treatment showed the same lack of significance among the four treatment groups. The figure shows the changes in wellbeing, concentrations of C reactive protein, and number of tender joints in the 57 patients who completed the study. All four groups showed substantial improvement in clinical and laboratory measures when they were assessed 12 months after starting treatment. Fified of pulse treatment with methyiprednisolone compared with placebo onl patients with rheumatoid arthritis receiving disease modifying drugs given placebo, headache by 26 and seven respectively, subjective dislike of treatment by 22 and three, disturbances of sense of taste by 16 and four, and tachycardia by 15 and six. All these adverse reactions were significantly more common in the treated groups (p<OO05). Only five patients complained of abdominal pain.
A comparison of the treatment groups showed no difference in the number of drop outs due to penicillamine or azathioprine.
Discussion
It is well established that pulse treatment with the conventional regimen of 1000 mg methylprednisolone intravenously for one to three days gives rapid temporary relief of flares in rheumatoid arthritis.'-3
The effect, however, is short lived. In our study we did not detect any effect on disease activity four weeks after each 1000 mg dose of methylprednisolone was given.
Previously, we examined the short term effect of 1000 mg methyiprednisolone daily for three consecutive days and found that, as judged by the erythrocyte sedimentation rate, the effect on pain and joint tenderness lasted for a maximum of four to eight weeks and that on inflammation for roughly two weeks.
The conventional treatment regimens use a dose of 1000 mg methylprednisolone daily for one to three days, and no significant differences have been seen among different dose regimens.8 Oral prednisolone would probably provide the same benefit at these doses. 49 In contrast to our findings Liebling et al'°reported that monthly pulses of 1000 mg methylprednisolone over six months gave substantially better clinical results than placebo, as evaluated by the number of tender joints, walking time, and strength of grip. The study, however, included only 10 patients and did not relate the pulse treatment to the type and duration of concomitant treatment with disease modifying drugs.
Other studies suggested that pulse treatment with methylprednisolone might enhance and accelerate the response to drugs that induce remission.' 6 The suggestions of Neuman et al,6 however, are partly based on a comparison with historical data, and no placebo group was included in either study.
We found that infusion with 1000 mg of methylprednisolone once a month for six months did not intensify the clinical or biochemical effects oftreatment with the disease modifying antirheumatic drugs penicillamine and azathioprine. In all groups the degree of improvement was similar, probably owing to the treatment with the disease modifying drug(s). We conclude that repeated pulses of methylprednisolone during the first six months of treatment with disease modifying antirheumatic drugs such as penicillamine and azathioprine do not improve the effect of these drugs. 
ONE HUNDRED YEARS AGO
In respect of a statement alleging that the Australian Government had refused to allow M. Pasteur the reward of £20,000 offered to the person who should suggest the best plan for the destruction of the rabbits that infest that colony, M. Pasteur is reported to have said that this was not so, for the simple reason that he had never sought it, and that, owing to circumstances over which he had no control, he could not claim such a reward. He had sent M. Loir, his nephew, and another of his assistants to Australia in order to try the experiments which he had made in his laboratory on a more extended scale. The assistants returned to France after a few months, discouraged. According to M. Pasteur, they were not allowed by the Commission appointed by the Australian Government to make any important experiments. This Commission permitted the assistants to inoculate a few rabbits, and the experiments were successful enough to warrant a further extension of the authorisation; but all sorts of delays and adjournments were caused, until the assistants abandoned all hope of being able to carry out the purpose for which they had undertaken the voyage to Australia.
(British Medical Joumal 1890;i:615)
